In this article, we will take a look at some of the stocks in Eashwar Krishnan’s Tybourne Capital Management portfolio. You can skip our detailed discussion and go to see 5 Stocks in Eashwar Krishnan’s Tybourne Capital Management Portfolio.
Eashwar Krishnan serves as the portfolio manager at Tybourne Capital Management, an investment management firm based in Hong Kong. Prior to Krishnan’s role at Tybourne Capital Management, he served as the Asia head of Lone Pine Capital for 11 years. He holds a Bachelor’s degree in Physics from St. Stephen’s College, Delhi, India, after which he did his Master’s from Cambridge University.
Eashwar Krishnan of Tybourne Capital Management
Our Methodology
We used Tybourne’s Q3 portfolio for this analysis.
8 Stocks in Eashwar Krishnan’s Tybourne Capital Management Portfolio
8. Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)
Tybourne Capital Management’s Stake Value: $5.5 million
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) is essentially a clinical-stage pharmaceutical company. It focuses primarily on the development of therapies for patients with rare genetic mitochondrial diseases. Headquartered in San Diego, California, the company was founded in 2014.
Tybourne Capital Management owns a $5.5 million stake in the company.
7. Cloopen Group Holding Limited (NYSE:RAAS)
Tybourne Capital Management’s Stake Value: $5.4 million
Cloopen Group Holding Limited (NYSE:RAAS) presents cloud-based communications solutions. The company offers covering communications platform as a service (CpaaS), cloud-based contact centers and cloud-based unified communications and collaborations. Cloopen Group Holding Limited (NYSE:RAAS) also provides services to several industries including the internet, telecommunications, financial services, education, industrial manufacturing and energy.
Tybourne Capital Management owns a $5.4 million stake in Cloopen Group Holding Limited’s (NYSE:RAAS). On 3rd September, Citi initiated coverage of the stock with a “Buy” rating and a price target of $27.
6. Taysha Gene Therapies, Inc. (NASDAQ:TSHA)
Tybourne Capital Management’s Stake Value: $9.3 million
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a gene therapy company that primarily focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company has a Taysha Gene partnership with The University of Texas Southwestern Medical Center and with Yale University to further its research.
Tybourne Capital Management owns a $9.3 million stake in the company. As of the end of September 2021, Raju Prasad from William Blair maintained a “Buy” rating on Taysha Gene Therapies, Inc. (NASDAQ: TSHA).
Click to continue reading and see 5 Stocks in Eashwar Krishnan’s Tybourne Capital Management Portfolio.
Suggested articles:
- Hedge Funds Aren’t Crazy About Pinduoduo Inc. (PDD) Anymore
- Otis Worldwide Corporation (OTIS) Fell Out Of Favor With Hedge Funds
- Hedge Funds Are Snapping Up Newmont Corporation (NEM)
Disclosure: None. 8 Stocks in Eashwar Krishnan’s Tybourne Capital Management Portfolio. is originally published on Insider Monkey.
